Heparanase inhibitors may be effective against tumors in which leukocyte-heparanase aids tumor progression, such as colorectal and pancreatic carcinoma (52), but perhaps less effective against other solid tumors which have little heparanase expression in the tumor microenvironment. This evidence concerns the gene HPSE and neoplasm.